DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia

Information source: Ruijin Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Arbitrary Restriction Polymorphism 1

Phase: N/A

Status: Recruiting

Sponsored by: Ruijin Hospital

Official(s) and/or principal investigator(s):
Wan-Hua Yang, Prof., Study Director, Affiliation: Ruijin Hospital

Overall contact:
Juan He, Phone: 86-21-64370045, Ext: 664405, Email: hejuanwin@126.com

Summary

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.

Clinical Details

Official title: Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia

Study design: Observational Model: Case Control, Time Perspective: Retrospective

Primary outcome: vancomycin serum trough concentrations in these patients just prior to the next vancomycin serum trough concentrations was measured

Secondary outcome: the pharmacokinetic parameters was calculated using the Bayesian estimator.

Detailed description: The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent. After reviewing more than 6000 clinical charts of patients who received vancomycin therapy and whose serum vancomycin level was monitored between January 2010 and December 2013, we identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and 98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The fluorescence polarization immunoassay method was used to measure vancomycin serum trough concentrations in these patients 30 min before the next administration. Using these measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator.

Eligibility

Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- age 18-85years old

- vancomycin use ≥ 3days

Exclusion Criteria:

- age <18years old or >85 years old

- vancomycin use < 3days

Locations and Contacts

Juan He, Phone: 86-21-64370045, Ext: 664405, Email: hejuanwin@126.com

Ruijin Hospital, Shanghai, Shanghai 200025, China; Recruiting
He, Phone: 86-21-64370045, Ext: 662618
Additional Information

Starting date: May 2013
Last updated: May 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017